Compare ARK Genomic Revolution ETF (ARKG) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Vanguard Short Term Corporate Bond ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Vanguard Short Term Corporate Bond ETF trades at $78.7. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | VCSH | |
|---|---|---|
Sector | Sector/Thematic | Fixed Income |
52-Week High | $43.57 | $80.20 |
52-Week Low | $23.09 | $78.61 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
VCSH trades at $78.61, down 0.1% with a bearish technical outlook showing 16 sell signals versus 1 buy. The ETF maintains consistent dividend distributions with recent payments of $0.29-$0.30 per share. News coverage highlights VCSH's competitive expense ratio and yield advantages over comparable short-term bond ETFs, though institutional positions show mixed adjustments.
The short-term corporate bond ETF faces headwinds from the Fed's indication of no rate cuts in 2026, potentially limiting near-term upside. Current technical weakness suggests cautious positioning, though the neutral oscillator reading and institutional interest from firms like BlueSky Wealth Advisors provide some support. The primary risk remains interest rate sensitivity in the current monetary policy environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
